EVOTEC SEINH O.N. news, videos and press releases - Page 7
For more news please use our advanced search feature.
EVOTEC SEINH O.N. - More news...
EVOTEC SEINH O.N. - More news...
- Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
- DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
- Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
- DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
- Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
- DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022
- Evotec SE Reports First Half-year 2022 Results on 11 August 2022
- DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
- Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance
- DGAP-News: Evotec completes acquisition of Rigenerand
- Evotec Completes Acquisition of Rigenerand
- DGAP-News: Evotec SE reports results of Annual General Meeting 2022
- Evotec SE Reports Results of Annual General Meeting 2022
- DGAP-News: Evotec enters a drug discovery collaboration with Janssen
- Evotec Enters a Drug Discovery Collaboration with Janssen
- DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
- Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand
- DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
- Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
- DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
- Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes
- DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update
- DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
- DGAP-Adhoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership
- Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
- Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
- DGAP-News: Evotec SE to announce results for the first quarter 2022 on 11 May 2022
- Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022
- DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
- Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
